Marie‐Ange Mouret‐Reynier
Centre Jean Perrin(FR)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Genomics and Diagnostics
Most-Cited Works
- → Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial(2022)643 cited
- → Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis(2016)399 cited
- → Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer(2010)386 cited
- → Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial(2017)379 cited
- → Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer(2024)335 cited
- → Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial(2022)291 cited
- → Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort(2018)277 cited
- → Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer(2018)167 cited
- → Genomics to select treatment for patients with metastatic breast cancer(2022)160 cited
- → Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial(2020)158 cited